alogliptin
alogliptin is listed in the FDA National Drug Code directory with 9 NDC codes, marketed under brand name including Nesina. Available dosage form: tablet, film coated.
Drug Details
- Generic Name
- alogliptin
- Brand Names
- Nesina
- Application Number
- NDA022271
- Sponsor
- Takeda Pharmaceutical Co LTD
- NDC Codes
- 9
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- ALOGLIPTIN BENZOATE
Indications and Usage
1 INDICATIONS AND USAGE OSENI is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. OSENI is a combination of alogliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone, a thiazolidinedione agonist of peroxisome proliferator receptor gamma, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: OSENI is not recommended for use in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use OSENI is not recommended for use in patients with type 1 diabetes mellitus.